CA2713338C - Recombinant virus production using mammalian cells in suspension - Google Patents

Recombinant virus production using mammalian cells in suspension Download PDF

Info

Publication number
CA2713338C
CA2713338C CA2713338A CA2713338A CA2713338C CA 2713338 C CA2713338 C CA 2713338C CA 2713338 A CA2713338 A CA 2713338A CA 2713338 A CA2713338 A CA 2713338A CA 2713338 C CA2713338 C CA 2713338C
Authority
CA
Canada
Prior art keywords
suspension
mammalian cells
recombinant virus
virus production
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2713338A
Other languages
French (fr)
Other versions
CA2713338A1 (en
Inventor
Dave Knop
Darby Thomas
Gabor Veres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beacon Therapeutics Ltd
Original Assignee
Applied Genetic Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetic Technologies Corp filed Critical Applied Genetic Technologies Corp
Publication of CA2713338A1 publication Critical patent/CA2713338A1/en
Application granted granted Critical
Publication of CA2713338C publication Critical patent/CA2713338C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention generally provides methods for producing recombinant AAV viral particles using cells grown in suspension. The invention provides recombinant AAV particles for use in methods for delivering genes encoding therapeutic proteins, and methods for using the recombinant AAV particles in gene therapy.
CA2713338A 2008-01-29 2009-01-29 Recombinant virus production using mammalian cells in suspension Active CA2713338C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6281908P 2008-01-29 2008-01-29
US61/062,819 2008-01-29
PCT/US2009/000577 WO2009097129A1 (en) 2008-01-29 2009-01-29 Recombinant virus production using mammalian cells in suspension

Publications (2)

Publication Number Publication Date
CA2713338A1 CA2713338A1 (en) 2009-08-06
CA2713338C true CA2713338C (en) 2021-10-26

Family

ID=40913147

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2713338A Active CA2713338C (en) 2008-01-29 2009-01-29 Recombinant virus production using mammalian cells in suspension

Country Status (7)

Country Link
US (3) US20110229971A1 (en)
EP (1) EP2242840B1 (en)
AU (1) AU2009209408B2 (en)
CA (1) CA2713338C (en)
DK (1) DK2242840T3 (en)
ES (1) ES2751999T3 (en)
WO (1) WO2009097129A1 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3591055A1 (en) * 2011-01-07 2020-01-08 Applied Genetic Technologies Corporation Promoters derived from the 5' nontranslated region (5'-ntr) of the human cyclic nucleotide gated beta 3 (cngb3) gene, expression cassettes and vectors comprising said promoters, for use treating achromatopsia and other diseases
GB201103062D0 (en) 2011-02-22 2011-04-06 Isis Innovation Method
US10196636B2 (en) 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
WO2012145597A2 (en) * 2011-04-21 2012-10-26 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
SG11201509419QA (en) 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US9644216B2 (en) 2013-11-26 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors for treatment of glycogen storage disease
JP6635942B2 (en) * 2014-04-15 2020-01-29 アプライド ジェネティック テクノロジーズ コーポレイション Codon-optimized nucleic acid encoding retinitis pigmentosa GTPase regulator (RPGR)
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US11827680B2 (en) * 2014-11-06 2023-11-28 Case Western Reserve University Compounds and methods of treating usher syndrome III
CN107207556B (en) 2014-11-14 2020-12-08 沃雅戈治疗公司 regulatory polynucleotide
CN114717264A (en) 2014-11-14 2022-07-08 沃雅戈治疗公司 Compositions and methods for treating amyotrophic lateral sclerosis (ALS)
WO2016086227A2 (en) * 2014-11-26 2016-06-02 The Regents Of The University Of California Therapeutic compositions comprising transcription factors and methods of making and using the same
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
US10415044B2 (en) 2014-12-23 2019-09-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors encoding modified G6PC and uses thereof
IL315273A (en) 2015-01-16 2024-10-01 Univ Washington New microdystrophins and associated method of use
EP3719134B1 (en) 2015-03-11 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
EP3626274B1 (en) 2015-04-16 2025-01-22 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
KR20180002706A (en) 2015-04-23 2018-01-08 워싱턴 스테이트 유니버시티 Smad7 gene delivery as a therapeutic
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2016341983B8 (en) 2015-10-21 2022-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING AN ADENO-ASSOCIATED VIRUS (AAV)
SI3411484T1 (en) 2016-02-05 2023-12-29 Emory University Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Preparations and methods for treating Huntington's disease
KR102652994B1 (en) 2016-05-18 2024-04-01 보이저 테라퓨틱스, 인크. Modulatory polynucleotides
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
US20190367944A1 (en) 2017-01-30 2019-12-05 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
CN111108198A (en) 2017-05-05 2020-05-05 沃雅戈治疗公司 Compositions and methods for treating Huntington's disease
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND TREATMENT METHODS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN111108196A (en) 2017-05-09 2020-05-05 爱莫里大学 Coagulation factor variants and uses thereof
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
AU2018302016A1 (en) 2017-07-17 2020-02-06 The Regents Of The University Of California Trajectory array guide system
KR102883778B1 (en) 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Gene therapy for the treatment of type II mucopolysaccharidosis
WO2019067840A1 (en) 2017-09-29 2019-04-04 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
CA3077426A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CA3091810A1 (en) 2018-03-02 2019-09-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
EP3787771A1 (en) 2018-04-29 2021-03-10 REGENXBIO Inc. Scalable clarification process for recombinant aav production
WO2019212922A1 (en) 2018-04-29 2019-11-07 Regenxbio Inc. Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
IL279193B2 (en) 2018-06-14 2025-07-01 Regenxbio Inc Anion exchange chromatography for recombinant aav production
EP3818161A1 (en) 2018-07-02 2021-05-12 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CN110699367B (en) * 2018-07-09 2021-06-11 武汉纽福斯生物科技有限公司 Nucleic acid for coding human NADH dehydrogenase subunit 4 protein and application thereof
MX2021000810A (en) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Systems and methods for producing gene therapy formulations.
US20210163991A1 (en) 2018-08-10 2021-06-03 Regenxbio Inc. Scalable method for recombinant aav production
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (en) 2018-10-04 2020-10-01 美商航海家醫療公司 Methods for measuring the titer and potency of viral vector particles
US20210324483A1 (en) 2018-10-15 2021-10-21 Regenxbio Inc. Method for measuring the infectivity of replication defective viral vectors and viruses
AU2019405758B2 (en) 2018-12-18 2026-02-05 Ultragenyx Pharmaceutical Inc. Methods and compositions for treating glycogen storage diseases
PL3906066T3 (en) 2019-01-04 2024-09-02 Ultragenyx Pharmaceutical Inc. Gene therapy constructs for treating wilson disease
TW202039858A (en) 2019-01-18 2020-11-01 美商航海家醫療公司 Methods and systems for producing aav particles
MX2021008832A (en) 2019-02-08 2021-09-08 Krystal Biotech Inc COMPOSITIONS AND METHODS FOR ADMINISTRATION OF CFTR POLYPEPTIDES.
JP2022522166A (en) 2019-02-28 2022-04-14 ベニテック アイピー ホールディングス インコーポレーテッド Compositions and Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)
DK3953483T3 (en) 2019-04-11 2023-12-18 Regenxbio Inc SIZE CHROMATOGRAPHY METHODS FOR CHARACTERIZING COMPOSITIONS OF RECOMBINANT ADENO-ASSOCIATED VIRUS
US20220143115A1 (en) 2019-04-19 2022-05-12 Regenxbio Inc. Adeno-Associated Virus Vector Formulations and Methods
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
EP4077688A1 (en) * 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
JP7703543B2 (en) 2020-01-17 2025-07-07 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Gene therapy for the treatment of CRX autosomal dominant retinopathy - Patents.com
KR20220140537A (en) 2020-02-14 2022-10-18 울트라제닉스 파마수티컬 인코포레이티드 Gene therapy to treat CDKL5 deficiency disorder
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
CN112107696A (en) * 2020-09-14 2020-12-22 台州和和生物科技有限公司 Innovative gene therapy medicine for special route administration and medicine box thereof
US20230383278A1 (en) 2020-09-18 2023-11-30 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
KR20230120128A (en) 2020-12-16 2023-08-16 리젠엑스바이오 인크. Methods for producing recombinant viral particles
WO2022159662A1 (en) 2021-01-21 2022-07-28 Regenxbio Inc. Improved production of recombinant polypeptides and viruses
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4322975A4 (en) * 2021-04-14 2025-03-26 Capsida, Inc. Plasmids and methods of production of adeno-associated viruses
WO2023018854A2 (en) 2021-08-11 2023-02-16 Solid Biosciences Inc. Treatment of muscular dystrophy
CN115873987A (en) * 2021-09-30 2023-03-31 北京五加和基因科技有限公司 Method and kit for detecting infection titer of adeno-associated virus vector
CN118202060A (en) 2021-10-05 2024-06-14 再生生物股份有限公司 Compositions and methods for recombinant AAV production
WO2023060113A1 (en) 2021-10-05 2023-04-13 Regenxbio Inc. Compositions and methods for recombinant aav production
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
US20250213727A1 (en) 2022-03-25 2025-07-03 Regenxbio Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2023239627A2 (en) 2022-06-08 2023-12-14 Regenxbio Inc. Methods for recombinant aav production
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024168358A1 (en) 2023-02-10 2024-08-15 Expression Therapeutics, Llc Lentiviral system
EP4669654A1 (en) 2023-02-22 2025-12-31 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant adeno-associated viral vectors without immunodominant T-cell epitope and use thereof
AU2024240009A1 (en) 2023-03-17 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
EP4689137A1 (en) 2023-04-07 2026-02-11 REGENXBIO Inc. Compositions and methods for recombinant aav production
WO2024233529A2 (en) 2023-05-07 2024-11-14 Regenxbio Inc. Compositions and methods for recombinant aav production
WO2025090962A1 (en) 2023-10-25 2025-05-01 Regenxbio Inc. Compositions and methods for recombinant aav production
WO2025106374A1 (en) 2023-11-13 2025-05-22 Juno Therapeutics, Inc. Aav production method
WO2026017965A1 (en) 2024-07-19 2026-01-22 The University Court Of The University Of Edinburgh Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
DE4438833A1 (en) * 1994-10-31 1996-05-02 Bayer Ag Method for the analytical separation of viruses
DE19830141A1 (en) * 1998-07-06 2000-01-13 Regine Heilbronn Recombinant herpes viruses for the generation of recombinant adeno-associated viruses
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
GB2375479B (en) * 2002-02-23 2003-03-26 Beldore Ltd Waste water outlet unit
US7091029B2 (en) 2002-09-23 2006-08-15 Applied Genetics Technologies Corporation High titer recombinant AAV production
US20070202587A1 (en) 2002-09-23 2007-08-30 Applied Genetic Technologies Corporation Recombinant AAV production in mammalian cells
WO2007059473A2 (en) 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
US20110014232A1 (en) * 2009-07-16 2011-01-20 Agricultural Research Council Chimeric foot and mouth disease viruses

Also Published As

Publication number Publication date
AU2009209408A1 (en) 2009-08-06
US20180312872A1 (en) 2018-11-01
EP2242840A4 (en) 2012-12-19
US20110229971A1 (en) 2011-09-22
DK2242840T3 (en) 2019-10-21
CA2713338A1 (en) 2009-08-06
EP2242840B1 (en) 2019-07-24
EP2242840A1 (en) 2010-10-27
US9783826B2 (en) 2017-10-10
ES2751999T3 (en) 2020-04-02
WO2009097129A1 (en) 2009-08-06
US20130244331A1 (en) 2013-09-19
AU2009209408B2 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
CA2713338C (en) Recombinant virus production using mammalian cells in suspension
CY1124905T1 (en) Variant CAPSID-ASSOCIATED VIRUS VIRUS PARTICLES AND METHODS OF USING THEREOF
WO2010138263A3 (en) Novel aav 's and uses thereof
US20180327706A1 (en) Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
MX2021000211A (en) Methods and products for transfecting cells.
EP4372008A3 (en) Tropism-modified recombinant viral vectors and uses thereof for the targeted introduction of genetic material into human cells
MX340102B (en) A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy.
WO2008156702A3 (en) Bacteria mediated gene silencing
WO2009120762A3 (en) Human cardiovascular progenitor cells
MX2014003744A (en) Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces.
EP2330200A3 (en) Gene expression technique
WO2011139379A3 (en) A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
AU2009201827B2 (en) Nerve regeneration
WO2014186160A8 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
WO2008122811A3 (en) Adenoviral vectors encoding a pathogen or tumour antigen
WO2005086667A3 (en) High efficiency peptide production in plant cells
WO2013119371A3 (en) Mini-intronic plasmid vectors
WO2011039646A3 (en) Papilloma virus -like particles for targeted gene delivery
WO2012094193A3 (en) Methods for enhancing the delivery of gene-transduced cells
WO2019089034A1 (en) Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
WO2010098561A3 (en) Novel beta-galactosidase having a high transglycosylation activity, and a use therefor
WO2013046216A8 (en) Two plasmid mammalian expression system
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140107